2026-03-14T13:07:44Z https://repository.lib.tottori-u.ac.jp/oai

oai:repository.lib.tottori-u.ac.jp:00004631 2023-09-28T23:47:02Z 1:9 2:12 23:34:978:979

Predictive Model for Adverse Events and Immune Response Based on the Production of Antibodies After the Second-Dose of the BNT162b2 mRNA Vaccine 50343281 岡田, 晋一 オカダ, シンイチ Okada, Shinichi Tomita, Katsuyuki トミタ, カツユキ 唐下, 泰一 トウゲ, ヒロカズ 60189529 長谷川, 純一 ハセガワ, ジュンイチ Hasegawa, Junichi 70325009 山崎, 章 ヤマサキ, アキラ Yamasaki, Akira Tomita, Katsuyuki トミタ, カツユキ Inui, Genki Ikeuchi, Tomoyuki Touge, Hirokazu トウゲ, ヒロカズ (C) 2022 Tottori University Medical Press. adverse effect antibody BNT162b2 vaccine classification and regression tree adverse effect antibody BNT162b2 vaccine classification and regression tree Background: The BNT162b mRNA vaccine for coronavirus disease 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), mimics the immune response to natural infection. Few studies have predicted the adverse effects (AEs) after the second-dose vaccination. We present a predictive model for AEs and immune response after the second-dose of the BNT162b mRNA vaccine. Methods: To predict AEs, 282 healthcare workers (HCWs) were enrolled in this prospective observational study. The classification and regression tree (CART) model was established, and its predictive efficacy was assessed. To predict immune response, 282 HCWs were included in the analysis. Moreover, the factors affected by anti-SARS-CoV-2 spike protein RBD antibody (s-IgG) were evaluated using serum samples collected 2 months after the second-dose vaccination. The s-IgG level was assessed using Lumipulse G1200. Multiple regression analyses were conducted to evaluate variables associated with anti-s-IgG titer levels. Results: The most common AEs after the second-dose vaccination were pain (87.6%), redness (17.0%) at the injection site, fatigue (68.8%), headache (53.5%), and fever (37.5%). Based on the CART model, headache after the first-dose vaccination and age < 30 years were identified as the first and second discriminators for predicting the headache after the second-dose vaccination, respectively. In the multiple linear regression model, anti-s-IgG titer levels were associated with age, female sex, and AEs including headache and induration at the injection site after the second-dose vaccination. Conclusion: Headache after the first-dose vaccination can be a predictor of headache after the second-dose vaccination, and AEs are indicators of immune response. Tottori University Medical Press 2022-02-22 eng journal article VoR https://repository.lib.tottori-u.ac.jp/records/4631 10.33160/yam.2022.02.012 Yonago Acta Medica. 2022, 65(1), 63-69. doi:10.33160/yam.2022.02.012 https://www.lib.tottori-u.ac.jp/yam/yam/yam65-1/65-1contents.html https://www.lib.tottori-u.ac.jp/yam/yam/yam65-1/65-1contents.html https://doi.org/10.33160/yam.2022.02.012 https://doi.org/10.33160/yam.2022.02.012 AA00892882 05135710 Yonago Acta Medica Yonago Acta Medica 65 1 63 69 https://repository.lib.tottori-u.ac.jp/record/4631/files/yam65(1)_63.pdf application/pdf 1.1 MB 2023-03-15